[Skip to Navigation]
Comment & Response
February 2017

Insufficient Evidence of Cimetidine Benefit in Protoporphyria—Reply

Author Affiliations
  • 1Department of Dermatology, Stanford University, Palo Alto, California
  • 2College of Physicians and Surgeons, Columbia University, New York, New York
JAMA Dermatol. 2017;153(2):238. doi:10.1001/jamadermatol.2016.4050

In Reply We would like to thank Drs Langendonk and Wilson for their insightful comments that highlight the challenges of diagnosis and treatment of erythropoietic protoporphyria (EPP). We agree that data from the 3 cases may not be generalized until larger-scale rigorous clinical trials can be conducted. Nevertheless, the dramatic and rapid clinical improvements our patients experienced cannot be ignored. The overwhelming positive responses from the international EPP community have led us to believe that cimetidine has the potential to be a safe and effective addition to the management of EPP and warrants further study.

Add or change institution